Get the Stockscreener App
1.6999
9.27%
0.1349
Rein Therapeutics Inc stock is traded at $1.6999, with a volume of 32.61M.
It is up +9.27% in the last 24 hours and up +43.70% over the past month.
Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.
See More
Previous Close:
$1.565
Open:
$1.69
24h Volume:
32.61M
Relative Volume:
50.92
Market Cap:
$40.55M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+26.67%
1M Performance:
+43.70%
6M Performance:
-6.04%
1Y Performance:
+0.00%
1-Day Range:
$1.57
$1.76
1-Week Range:
$1.30
$1.76
52-Week Range:
$1.04
$3.50
Rein Therapeutics Inc Stock (RNTX) Company Profile
Name
Rein Therapeutics Inc
Sector
Industry
Phone
(737) 802-1989
Address
12407 N. MOPAC EXPY., AUSTIN
Compare RNTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RNTX
Rein Therapeutics Inc
|
1.7399 | 37.60M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.69 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.02 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
446.18 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
825.84 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.89 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Rein Therapeutics Inc Stock (RNTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-22-25 | Initiated | H.C. Wainwright | Buy |
| Jan-28-25 | Initiated | Rodman & Renshaw | Buy |
| Jul-24-17 | Initiated | BofA/Merrill | Buy |
| Jul-24-17 | Initiated | Jefferies | Buy |
| Jul-24-17 | Initiated | William Blair | Outperform |
Rein Therapeutics Inc Stock (RNTX) Latest News
Rein Therapeutics Receives FDA Clearance to Resume Phase 2 Trial - TradingView
Rein Therapeutics Receives FDA Clearance to Resume U.S. Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis - The Manila Times
How Rein Therapeutics Inc. stock reacts to bond yieldsJuly 2025 Setups & Daily Volume Surge Trade Alerts - newser.com
Ranking Rein Therapeutics Inc. among high performing stocks via toolsQuarterly Investment Review & Weekly Hot Stock Watchlists - newser.com
Technical signs of recovery in Rein Therapeutics Inc.July 2025 Catalysts & Community Consensus Stock Picks - newser.com
Multi asset correlation models including Rein Therapeutics Inc.Weekly Trend Summary & Daily Growth Stock Tips - newser.com
Why Rein Therapeutics Inc. stock attracts high net worth investorsTrade Analysis Summary & Weekly High Return Stock Opportunities - newser.com
News impact scoring models applied to Rein Therapeutics Inc.Weekly Trade Recap & Risk Controlled Swing Trade Alerts - newser.com
Price momentum metrics for Rein Therapeutics Inc. explainedEarnings Recap Report & Technical Analysis for Trade Confirmation - newser.com
Will Rein Therapeutics Inc. stock reach Wall Street targetsJuly 2025 Update & Short-Term Trading Opportunity Alerts - newser.com
Using economic indicators to assess Rein Therapeutics Inc. potential2025 AllTime Highs & Detailed Earnings Play Strategies - newser.com
Why retail investors pile into Rein Therapeutics Inc. stock2025 Breakouts & Breakdowns & Weekly Chart Analysis and Trade Guides - newser.com
Rein Therapeutics Inc. stock retracement – recovery analysis2025 Geopolitical Influence & AI Driven Price Predictions - newser.com
Rein Therapeutics Inc. Stock (RNTX) Opinions on Institutional Investments and Funding Deals - Quiver Quantitative
Is Rein Therapeutics Inc. stock a defensive play in 20252025 Market WrapUp & AI Based Trade Execution Alerts - fcp.pa.gov.br
How rising interest rates impact Rein Therapeutics Inc. stock2025 Growth vs Value & AI Driven Stock Reports - fcp.pa.gov.br
VIX Spike: How rising interest rates impact Rein Therapeutics Inc. stockBond Market & Real-Time Volume Analysis Alerts - fcp.pa.gov.br
Applying sector rotation models to Rein Therapeutics Inc.2025 Price Action Summary & Weekly Consistent Profit Watchlists - newser.com
Rein Therapeutics Inc Stock (RNTX) Financials Data
There is no financial data for Rein Therapeutics Inc (RNTX). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Rein Therapeutics Inc Stock (RNTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Voss Capital, LP | 10% Owner |
Oct 27 '25 |
Buy |
1.37 |
97,482 |
133,544 |
822,258 |
| Voss Capital, LP | 10% Owner |
Oct 24 '25 |
Buy |
1.39 |
30,176 |
41,957 |
729,616 |
| WINDSOR JAMES BRIAN | President and CEO |
Dec 05 '24 |
Buy |
2.24 |
400 |
898 |
239 |
0.03%
0.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):